Perrigo Company plc or MiMedx Group, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Companies

In the competitive landscape of pharmaceuticals and medical devices, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Perrigo Company plc and MiMedx Group, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Perrigo's SG&A expenses have consistently been higher, averaging around 1.1 billion annually, compared to MiMedx's more modest 188 million. However, the growth in MiMedx's SG&A costs, which surged by approximately 133% from 2014 to 2023, suggests a strategic expansion. Meanwhile, Perrigo's expenses grew by about 89%, indicating a more stable cost management approach. This data highlights the different strategies these companies employ in managing operational costs, reflecting their unique market positions and growth trajectories. As investors and analysts look for efficiency and growth, understanding these trends is key to making informed decisions.